Trial Profile
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Dec 2023
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary)
- Indications Neurofibromatosis 1; Plexiform neurofibroma
- Focus Therapeutic Use
- Acronyms NF108-BINI
- 04 Dec 2021 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 04 Dec 2021 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2025.
- 06 Jan 2021 Status changed from recruiting to active, no longer recruiting.